Oita University, Research Promotion Institute, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan.
Suzuka University of Medical Science, Faculty of Pharmaceutical Sciences, 3500-3 Minamitamagaki-cho, Suzuka 510-0293, Japan.
Sci Adv. 2020 Mar 25;6(13):eaay6441. doi: 10.1126/sciadv.aay6441. eCollection 2020 Mar.
Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro, a highly conserved residue in CDR-3 of the antibody light chain. The deletion of Pro is a key contributor to catalytic function of the light chain. The S35 and S38 light chains have identical amino acid sequences except for Pro. The former, with Pro did not show any catalytic activity, whereas the latter, without Pro, exhibited peptidase activity. To verify the generality of this finding, we tested another light chain, T99wt, which had Pro and showed little catalytic activity. In contrast, a Pro-deleted mutant enzymatically degraded the peptide substrate and amyloid-beta molecule. These two cases demonstrate the potential for a new method of creating catalytic antibodies from the corresponding mAbs.
迄今为止,已经生产了数千种单克隆抗体(mAbs),如果这些 mAbs 能够直接转化为催化抗体,将具有很高的价值。我们设计了一个系统来实现上述概念,方法是删除抗体轻链 CDR-3 中高度保守的脯氨酸。脯氨酸的缺失是轻链催化功能的关键贡献者。S35 和 S38 轻链除了脯氨酸外具有相同的氨基酸序列。前者含有脯氨酸,没有表现出任何催化活性,而后者不含脯氨酸,具有肽酶活性。为了验证这一发现的普遍性,我们测试了另一种含有脯氨酸且催化活性较低的轻链 T99wt。相比之下,缺失脯氨酸的突变体可以酶促降解肽底物和淀粉样β分子。这两种情况表明,从相应的 mAbs 中创建催化抗体的新方法具有潜力。